Our review on the impact of clonal hematopoiesis on clonally unrelated hematologic malignancies is out! Great to work on this with extremely bright fellows, both of whom are too bright to be on twitter (and also Christopher Dittus, DO, MPH calliecoombs)

📣 Join us August 18th 7:00 PM Eastern as we discuss #aging + #race + socioeconomic factors and the influence on #mmsm care within the #Black community. Thank you HealthTree for Multiple Myeloma (Myeloma Crowd) for hosting this wonderful event! I look forward to an interactive session! #geriheme #gerionc

Teclistamab in Relapsed or Refractory Multiple Myeloma | NEJM nejm.org/doi/full/10.10… Teclistamab in New England Journal of Medicine.

Calling all #mmsm peeps, please click the link below and register (live or virtual) for the #IMS2022 ! Previously known as the IMW that was held every 2 years, the IMS Meeting will be an Annual event. Hem-Onc Fellows Network Mohamad Mohty Graham jackson Anita D'Souza Surbhi Sidana, MD

In this year’s #ASCO22 research round up podcast👇🏾 by CancerDotNet I discuss 3 #gerionc studies:1) rural-urban status and GA imp. Grant R. Williams, MD, MSPH 2)e-frailty index by Heidi Klepin & 3)ASTER study by Etienne Brain Cancer and Aging Research Group (CARG) #GeriOnc cancer.net/blog/2022-07/2…

Proud and honored to have been part of this group! #mmsm

I have #COVID so I'm work from home, including my #mmsm clinic yesterday and today, which I did from my teenage son's bedroom. Today a patient complimented me on the sweet #IronMaiden poster hanging behind me.

Welcome to my clinic. I hope you enjoy the wall art. :D

Incredible... #mmsm

And myeloma! The review was actually inspired after seeing so many MM (and lymphoma) pts in my CHIP/CCUS clinic 🙂

.Sascha Tuchman, MD, MHS, specializes in hematology, and specifically multiple myeloma and amyloidosis. He collaborates with other UNC Lineberger clinicians and scientists, and works to cultivate the next generation of myeloma experts. go.unc.edu/k5SHc

Always a pleasure working with friends and colleagues across all specialties in the UNC amyloid program! Chris Jensen UNC Lineberger Sam Rubinstein #amyloidosis

Congrats to our great fellows! UNC Lineberger

Loving this excellent column by Keith Stewart !

Yesssss! Love it.

1/ The long-awaited DETERMINATION trial was published today synchronously with a plenary at ASCO. As with IFM-2009, upfront auto has a clinically and statistically significant PFS advantage, but OS same for both groups.

nejm.org/doi/suppl/10.1…

Ben Derman MyelomaLymphoma For Ben 👇🏽. Absence of evidence is not evidence of absence (quoting Rafael Fonseca MD 🇺🇸🏜🇲🇽)

DETERMINATION is out NEJM. ≈2 year-PFS benefit w upfront ASCT vs VRD-alone. PFS in high-risk pts.≈3x with ASCT (Fig. below). No OS benefit overall. MDS/AML 2.7% (vs none in VRD). Time to personalize upfront ASCT based on MRD & risk-status? tinyurl.com/22dh3ums #mmsm #ASCO22